Cambridge Healthtech Institute’s 5th Annual

Fusion Protein Therapeutics
( 融合蛋白质治疗药物 )

Engineering for Clinical Success



Chimeric fusion proteins, with their ability to extend plasma half-life and prolong therapeutic activity, offer exciting benefits over antibody-based therapeutics. Companies are intensely investigating into fusion protein therapeutics as a promising alternative to antibodies. The 5th Annual Fusion Protein Therapeutics will explore the latest developments and future prospects of this exciting modality by inviting researchers to present their novel Fc-fusion platforms, present updates from preclinical and clinical trials, and discuss engineering and conjugation strategies to improve efficacy, safety and clinical success.



Coverage will include, but is not limited to:


  • Novel Scaffolds and Platforms
    • peptide fusions, albumin fusions, immunotoxins, cytokine fusions, toxin-based fusions, nanoparticle fusions
  • Fusion Proteins in Immunotherapy
  • Engineering and Optimizing Fusion Proteins to:
    • extend half-life
    • reduce toxicity
    • improve targeting and binding
    • increase or decrease effector function
    • improve pharmacokinetics
    • optimize fused partner
  • Translational and Clinical Development
  • Fusion Proteins for Non-Oncology Indications

* 活动内容有可能不事先告知作更动及调整。

Choose your language